Spark Therapeutics, Inc. (ONCE) Receives “Buy” Rating from Cowen and Company

Cowen and Company reaffirmed their buy rating on shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) in a research note issued to investors on Tuesday. Cowen and Company currently has a $95.00 target price on the biotechnology company’s stock.

“The FDA’s briefing documents appear mostly benign with most discussion centered.”,” the firm’s analyst wrote.

A number of other equities analysts have also recently weighed in on ONCE. ValuEngine raised Spark Therapeutics from a sell rating to a hold rating in a report on Tuesday, June 20th. BidaskClub raised Spark Therapeutics from a sell rating to a hold rating in a report on Thursday, June 22nd. William Blair started coverage on Spark Therapeutics in a report on Wednesday, June 28th. They set an outperform rating for the company. Jefferies Group LLC started coverage on Spark Therapeutics in a report on Monday, July 10th. They set a buy rating and a $85.00 target price for the company. Finally, Zacks Investment Research cut Spark Therapeutics from a hold rating to a sell rating in a report on Wednesday, July 12th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and seventeen have assigned a buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of $88.38.

Shares of Spark Therapeutics (ONCE) opened at 86.74 on Tuesday. The company’s 50 day moving average price is $85.90 and its 200 day moving average price is $85.90. Spark Therapeutics has a 52-week low of $35.07 and a 52-week high of $91.00. The stock’s market cap is $2.71 billion.

Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.75) by ($0.14). The business had revenue of $1.48 million during the quarter, compared to analyst estimates of $1.33 million. Spark Therapeutics had a negative return on equity of 59.74% and a negative net margin of 962.72%. The business’s revenue for the quarter was up 14.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.04) EPS. On average, analysts anticipate that Spark Therapeutics will post ($7.67) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://stocknewstimes.com/2017/10/11/spark-therapeutics-inc-once-receives-buy-rating-from-cowen-and-company.html.

In other news, CFO Stephen W. Webster sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $79.38, for a total value of $793,800.00. Following the completion of the sale, the chief financial officer now directly owns 12,500 shares in the company, valued at $992,250. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Stephen W. Webster sold 2,337 shares of the company’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $71.12, for a total value of $166,207.44. Following the completion of the sale, the chief financial officer now owns 4,837 shares of the company’s stock, valued at $344,007.44. The disclosure for this sale can be found here. Insiders sold 1,333,195 shares of company stock valued at $109,070,506 over the last 90 days. Company insiders own 7.30% of the company’s stock.

Several hedge funds have recently bought and sold shares of ONCE. BlackRock Inc. grew its position in shares of Spark Therapeutics by 11,332.0% in the first quarter. BlackRock Inc. now owns 1,840,214 shares of the biotechnology company’s stock valued at $98,158,000 after purchasing an additional 1,824,117 shares in the last quarter. Janus Henderson Group PLC purchased a new stake in shares of Spark Therapeutics in the second quarter valued at approximately $30,848,000. Wellington Management Group LLP grew its position in shares of Spark Therapeutics by 119.5% in the first quarter. Wellington Management Group LLP now owns 808,782 shares of the biotechnology company’s stock valued at $43,140,000 after purchasing an additional 440,287 shares in the last quarter. Sectoral Asset Management Inc purchased a new stake in shares of Spark Therapeutics in the second quarter valued at approximately $6,052,000. Finally, Vanguard Group Inc. grew its position in shares of Spark Therapeutics by 5.3% in the second quarter. Vanguard Group Inc. now owns 1,924,463 shares of the biotechnology company’s stock valued at $114,968,000 after purchasing an additional 96,803 shares in the last quarter. Institutional investors and hedge funds own 77.84% of the company’s stock.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply